244 related articles for article (PubMed ID: 19017637)
1. Artemisinin blocks prostate cancer growth and cell cycle progression by disrupting Sp1 interactions with the cyclin-dependent kinase-4 (CDK4) promoter and inhibiting CDK4 gene expression.
Willoughby JA; Sundar SN; Cheung M; Tin AS; Modiano J; Firestone GL
J Biol Chem; 2009 Jan; 284(4):2203-13. PubMed ID: 19017637
[TBL] [Abstract][Full Text] [Related]
2. Artemisinin triggers a G1 cell cycle arrest of human Ishikawa endometrial cancer cells and inhibits cyclin-dependent kinase-4 promoter activity and expression by disrupting nuclear factor-κB transcriptional signaling.
Tran KQ; Tin AS; Firestone GL
Anticancer Drugs; 2014 Mar; 25(3):270-81. PubMed ID: 24296733
[TBL] [Abstract][Full Text] [Related]
3. Antiproliferative effects of artemisinin on human breast cancer cells requires the downregulated expression of the E2F1 transcription factor and loss of E2F1-target cell cycle genes.
Tin AS; Sundar SN; Tran KQ; Park AH; Poindexter KM; Firestone GL
Anticancer Drugs; 2012 Apr; 23(4):370-9. PubMed ID: 22185819
[TBL] [Abstract][Full Text] [Related]
4. Indole-3-carbinol inhibits CDK6 expression in human MCF-7 breast cancer cells by disrupting Sp1 transcription factor interactions with a composite element in the CDK6 gene promoter.
Cram EJ; Liu BD; Bjeldanes LF; Firestone GL
J Biol Chem; 2001 Jun; 276(25):22332-40. PubMed ID: 11297539
[TBL] [Abstract][Full Text] [Related]
5. Sp1 inhibits proliferation and induces apoptosis in vascular smooth muscle cells by repressing p21WAF1/Cip1 transcription and cyclin D1-Cdk4-p21WAF1/Cip1 complex formation.
Kavurma MM; Khachigian LM
J Biol Chem; 2003 Aug; 278(35):32537-43. PubMed ID: 12796485
[TBL] [Abstract][Full Text] [Related]
6. Artemisinin disrupts androgen responsiveness of human prostate cancer cells by stimulating the 26S proteasome-mediated degradation of the androgen receptor protein.
Steely AM; Willoughby JA; Sundar SN; Aivaliotis VI; Firestone GL
Anticancer Drugs; 2017 Oct; 28(9):1018-1031. PubMed ID: 28708672
[TBL] [Abstract][Full Text] [Related]
7. Transforming growth factor beta activates the promoter of cyclin-dependent kinase inhibitor p15INK4B through an Sp1 consensus site.
Li JM; Nichols MA; Chandrasekharan S; Xiong Y; Wang XF
J Biol Chem; 1995 Nov; 270(45):26750-3. PubMed ID: 7592908
[TBL] [Abstract][Full Text] [Related]
8. Phytochemical regulation of the tumor suppressive microRNA, miR-34a, by p53-dependent and independent responses in human breast cancer cells.
Hargraves KG; He L; Firestone GL
Mol Carcinog; 2016 May; 55(5):486-98. PubMed ID: 25789847
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the role of Sp1 and NF-Y in differential regulation of PTTG/securin expression in tumor cells.
Clem AL; Hamid T; Kakar SS
Gene; 2003 Dec; 322():113-21. PubMed ID: 14644503
[TBL] [Abstract][Full Text] [Related]
10. Regulation of Sp1 by cell cycle related proteins.
Tapias A; Ciudad CJ; Roninson IB; Noé V
Cell Cycle; 2008 Sep; 7(18):2856-67. PubMed ID: 18769160
[TBL] [Abstract][Full Text] [Related]
11. Molecular interplay between cdk4 and p21 dictates G0/G1 cell cycle arrest in prostate cancer cells.
Gulappa T; Reddy RS; Suman S; Nyakeriga AM; Damodaran C
Cancer Lett; 2013 Sep; 337(2):177-83. PubMed ID: 23684928
[TBL] [Abstract][Full Text] [Related]
12. Honokiol causes G0-G1 phase cell cycle arrest in human prostate cancer cells in association with suppression of retinoblastoma protein level/phosphorylation and inhibition of E2F1 transcriptional activity.
Hahm ER; Singh SV
Mol Cancer Ther; 2007 Oct; 6(10):2686-95. PubMed ID: 17938262
[TBL] [Abstract][Full Text] [Related]
13. Selenium inhibition of survivin expression by preventing Sp1 binding to its promoter.
Chun JY; Hu Y; Pinder E; Wu J; Li F; Gao AC
Mol Cancer Ther; 2007 Sep; 6(9):2572-80. PubMed ID: 17876054
[TBL] [Abstract][Full Text] [Related]
14. Knockdown of protein tyrosine phosphatase SHP-1 inhibits G1/S progression in prostate cancer cells through the regulation of components of the cell-cycle machinery.
Rodríguez-Ubreva FJ; Cariaga-Martinez AE; Cortés MA; Romero-De Pablos M; Ropero S; López-Ruiz P; Colás B
Oncogene; 2010 Jan; 29(3):345-55. PubMed ID: 19838216
[TBL] [Abstract][Full Text] [Related]
15. 1,25-dihydroxyvitamin D3 transcriptionally represses p45Skp2 expression via the Sp1 sites in human prostate cancer cells.
Huang YC; Hung WC
J Cell Physiol; 2006 Nov; 209(2):363-9. PubMed ID: 16883603
[TBL] [Abstract][Full Text] [Related]
16. Histone deacetylase inhibitors activate INK4d gene through Sp1 site in its promoter.
Yokota T; Matsuzaki Y; Miyazawa K; Zindy F; Roussel MF; Sakai T
Oncogene; 2004 Jul; 23(31):5340-9. PubMed ID: 15107822
[TBL] [Abstract][Full Text] [Related]
17. Regulation of KLF5 involves the Sp1 transcription factor in human epithelial cells.
Chen C; Zhou Y; Zhou Z; Sun X; Otto KB; Uht RM; Dong JT
Gene; 2004 Apr; 330():133-42. PubMed ID: 15087132
[TBL] [Abstract][Full Text] [Related]
18. Sp1 Mediates the Constitutive Expression and Repression of the PDSS2 Gene in Lung Cancer Cells.
Hu L; Chen Q; Wang Y; Zhang N; Meng P; Liu T; Bu Y
Genes (Basel); 2019 Nov; 10(12):. PubMed ID: 31783675
[TBL] [Abstract][Full Text] [Related]
19. Geldanamycin, an inhibitor of the chaperone activity of HSP90, induces MAPK-independent cell cycle arrest.
Bedin M; Gaben AM; Saucier C; Mester J
Int J Cancer; 2004 May; 109(5):643-52. PubMed ID: 14999769
[TBL] [Abstract][Full Text] [Related]
20. Indole-3-carbinol mediated cell cycle arrest of LNCaP human prostate cancer cells requires the induced production of activated p53 tumor suppressor protein.
Hsu JC; Dev A; Wing A; Brew CT; Bjeldanes LF; Firestone GL
Biochem Pharmacol; 2006 Dec; 72(12):1714-23. PubMed ID: 16970927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
